About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a company based in Menlo Park (United States) founded in 2018.. Mirum Pharmaceuticals has raised $120 million across 3 funding rounds from investors including Frazier Healthcare Partners, Oberland Capital and NEA. The company has 322 employees as of December 31, 2024. Mirum Pharmaceuticals has completed 2 acquisitions, including Bluejay Therapeutics and Satiogen. Mirum Pharmaceuticals offers products and services including LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program. Mirum Pharmaceuticals operates in a competitive market with competitors including Alnylam, Ultragenyx, NGM Biopharmaceuticals, BioMarin Pharmaceutical and Nimbus Therapeutics, among others.
- Headquarter Menlo Park, United States
- Employees 322 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mirum Pharmaceuticals, Inc.
-
Annual Revenue
$336.89 M80.76as on Dec 31, 2024
-
Net Profit
$-87.94 M46.18as on Dec 31, 2024
-
EBITDA
$-63.98 M34.93as on Dec 31, 2024
-
Total Equity Funding
$120 M (USD)
in 3 rounds
-
Latest Funding Round
$68.48 M (USD), Post-IPO
Jan 23, 2026
-
Investors
Frazier Healthcare Partners
& 7 more
-
Employee Count
322
as on Dec 31, 2024
-
Investments & Acquisitions
Bluejay Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mirum Pharmaceuticals
Mirum Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol MIRM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mirum Pharmaceuticals
Mirum Pharmaceuticals offers a comprehensive portfolio of products and services, including LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for cholestasis in rare diseases patients.
Therapy for inborn errors of bile acid metabolism.
Support for genetic neurology conditions in patients.
Program for testing rare diseases through healthcare partners.
Unlock access to complete
Unlock access to complete
Leadership Team
57 people
Software Development Team
24 people
Sales and Marketing
14 people
Product Management Team
8 people
Finance and Accounting
8 people
Senior Team
8 people
Regional Team
6 people
Board Team
5 people
Unlock access to complete
Funding Insights of Mirum Pharmaceuticals
Mirum Pharmaceuticals has successfully raised a total of $120M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $68.48 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $68.5M
-
First Round
First Round
(07 Nov 2018)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Post-IPO - Mirum Pharmaceuticals | Valuation |
investors |
|
| Dec, 2020 | Amount | Post-IPO - Mirum Pharmaceuticals | Valuation |
investors |
|
| Nov, 2018 | Amount | Series A - Mirum Pharmaceuticals | Valuation | New Enterprise Associates |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mirum Pharmaceuticals
Mirum Pharmaceuticals has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Frazier Healthcare Partners, Oberland Capital and NEA. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mirum Pharmaceuticals
Mirum Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bluejay Therapeutics and Satiogen. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for infectious diseases treatment are developed.
|
2019 | ||||
|
Specialty pharma company focused on developing treatment for
diabetes
|
2007 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Mirum Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mirum Pharmaceuticals Comparisons
Competitors of Mirum Pharmaceuticals
Mirum Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, NGM Biopharmaceuticals, BioMarin Pharmaceutical and Nimbus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mirum Pharmaceuticals
Frequently Asked Questions about Mirum Pharmaceuticals
When was Mirum Pharmaceuticals founded?
Mirum Pharmaceuticals was founded in 2018.
Where is Mirum Pharmaceuticals located?
Mirum Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Who is the current CEO of Mirum Pharmaceuticals?
Christopher Peetz is the current CEO of Mirum Pharmaceuticals.
Is Mirum Pharmaceuticals a funded company?
Mirum Pharmaceuticals is a funded company, having raised a total of $120M across 3 funding rounds to date. The company's 1st funding round was a Series A of $120M, raised on Nov 07, 2018.
How many employees does Mirum Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Mirum Pharmaceuticals is 322.
What is the annual revenue of Mirum Pharmaceuticals?
Annual revenue of Mirum Pharmaceuticals is $336.89M as on Dec 31, 2024.
What does Mirum Pharmaceuticals do?
Mirum Pharmaceuticals was founded in 2018 and is headquartered in Menlo Park, United States. Small molecule therapeutics are developed by the company to address rare diseases, focusing on cholestatic conditions. The lead candidate, Maralixibat, is targeted at Alagille syndrome and progressive familial intrahepatic cholestasis by inhibiting bile acid transport. Volixibat is being advanced for adult cholestasis. Operations center on pharmaceutical research and development in the rare disease sector.
Who are the top competitors of Mirum Pharmaceuticals?
Mirum Pharmaceuticals's top competitors include Alnylam, Nimbus Therapeutics and BioMarin Pharmaceutical.
What products or services does Mirum Pharmaceuticals offer?
Mirum Pharmaceuticals offers LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program.
Is Mirum Pharmaceuticals publicly traded?
Yes, Mirum Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol MIRM.
How many acquisitions has Mirum Pharmaceuticals made?
Mirum Pharmaceuticals has made 2 acquisitions, including Bluejay Therapeutics, and Satiogen.
Who are Mirum Pharmaceuticals's investors?
Mirum Pharmaceuticals has 8 investors. Key investors include Frazier Healthcare Partners, Oberland Capital, NEA, Deerfield, and Novo Holdings.
What is Mirum Pharmaceuticals's ticker symbol?
The ticker symbol of Mirum Pharmaceuticals is MIRM on NASDAQ.